ArticleJournal of nanobiotechnology2026
Neutrophil-mediated delivery of curcumin-loaded manganese-doped zeolitic imidazolate framework-8 nanozymes for pulmonary arterial hypertension.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Golgi-STING Signaling to Reprogram Innate and Adaptive Immunity for the Treatment of Implant-Associated Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is a severe vascular disease characterized by oxidative stress, inflammation, vascular remodeling, and endothelial‑to‑mesenchymal transition (EndoMT), leading to high pulmonary arterial pressure and right heart failure. Current therapies offer only symptomatic relief without reversing disease progression.
aimTo develop a targeted nanotherapeutic platform using neutrophil (NE)-mediated delivery of curcumin‑loaded manganese-doped zeolitic imidazolate framework-8 (Mn‑doped ZIF‑8) nanozymes for PAH treatment.
methodsWe constructed Mn‑ZIF‑8‑Cur@NEs (NEMZC) by loading Mn‑ZIF‑8‑Cur into primary neutrophils. The system was characterized by TEM, XRD, XPS, and drug release assays. In vitro and in vivo studies included transwell migration, immunofluorescence, flow cytometry, ELISA, Western blot, transcriptomics, echocardiography, right‑heart catheterization, and histology in a mouse PAH model.
resultsNEMZC showed high drug loading (encapsulation efficiency ~80%) and pH‑responsive release (82% curcumin release at pH < 6.0 within 12 h). It exhibited excellent targeting, with ~91.7% curcumin released within 4 h under inflammatory stimulation. In vitro, NEMZC reduced α‑SMA expression by 75% and increased CD31 expression by 3.3‑fold, indicating strong anti‑EndoMT effects. It also shifted macrophage polarization, decreasing M1 markers (iNOS by 75%) and increasing M2 markers (CD206 by ~3.2‑fold). In PAH mice, NEMZC reduced pulmonary arterial pressure from 57.2 mmHg to 20.7 mmHg, decreased collagen deposition by ~70%, and modulated the PI3K-NF‑κB pathway.
conclusionNEMZC represents a safe, targeted, and multifunctional cell‑based nanoplatform that effectively alleviates PAH through dual antioxidant/anti‑inflammatory action and EndoMT inhibition, demonstrating strong potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.